1. Sickle erythrocytes target cytotoxics to hypoxic tumor microvessels and potentiate a tumoricidal response
- Author
-
Gerald A. Grant, Joseph M. Eble, Richard J. Boruta, Kathleen A. Ashcraft, Rahima Zennadi, Mark W. Dewhirst, David S. Terman, Greg Palmer, Lan Lan, Yiting Cao, Marilyn J. Telen, Diane Renee Fels, Zahid N. Rabbani, Mathew R. Dreher, Benjamin L. Viglianti, Brian S. Sorg, Ejung Moon, and Hong Yuan
- Subjects
Cytotoxicity, Immunologic ,Pathology ,Cell ,Red Cells ,Cancer Treatment ,Protoporphyrins ,lcsh:Medicine ,Immunotherapy, Adoptive ,chemistry.chemical_compound ,Mice ,0302 clinical medicine ,Breast Tumors ,Tumor Microenvironment ,Hypoxia ,lcsh:Science ,0303 health sciences ,Multidisciplinary ,Neovascularization, Pathologic ,Cell adhesion molecule ,Hematology ,Combined Modality Therapy ,3. Good health ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Hemin ,Medicine ,Female ,Oncology Agents ,Antiangiogenesis Therapy ,medicine.symptom ,Research Article ,medicine.medical_specialty ,Heme Synthesis ,Blotting, Western ,Erythrocytes, Abnormal ,Mice, Nude ,Anemia, Sickle Cell ,Biology ,Microbiology ,03 medical and health sciences ,Gentamicin protection assay ,Cell Line, Tumor ,Virology ,medicine ,Animals ,Humans ,Clonogenic assay ,030304 developmental biology ,Tumor microenvironment ,Zinc protoporphyrin ,lcsh:R ,Membrane Proteins ,Cancers and Neoplasms ,Hydrogen Peroxide ,Neoplasms, Experimental ,Hypoxia (medical) ,Hemoglobinopathies ,chemistry ,Microscopy, Fluorescence ,Cancer research ,lcsh:Q ,Reactive Oxygen Species ,Heme Oxygenase-1 - Abstract
Resistance of hypoxic solid tumor niches to chemotherapy and radiotherapy remains a major scientific challenge that calls for conceptually new approaches. Here we exploit a hitherto unrecognized ability of sickled erythrocytes (SSRBCs) but not normal RBCs (NLRBCs) to selectively target hypoxic tumor vascular microenviroment and induce diffuse vaso-occlusion. Within minutes after injection SSRBCs, but not NLRBCs, home and adhere to hypoxic 4T1 tumor vasculature with hemoglobin saturation levels at or below 10% that are distributed over 70% of the tumor space. The bound SSRBCs thereupon form microaggregates that obstruct/occlude up to 88% of tumor microvessels. Importantly, SSRBCs, but not normal RBCs, combined with exogenous prooxidant zinc protoporphyrin (ZnPP) induce a potent tumoricidal response via a mutual potentiating mechanism. In a clonogenic tumor cell survival assay, SSRBC surrogate hemin, along with H(2)O(2) and ZnPP demonstrate a similar mutual potentiation and tumoricidal effect. In contrast to existing treatments directed only to the hypoxic tumor cell, the present approach targets the hypoxic tumor vascular environment and induces injury to both tumor microvessels and tumor cells using intrinsic SSRBC-derived oxidants and locally generated ROS. Thus, the SSRBC appears to be a potent new tool for treatment of hypoxic solid tumors, which are notable for their resistance to existing cancer treatments.
- Published
- 2021